Literature DB >> 1711541

Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen.

C Ferrari1, A Bertoletti, A Penna, A Cavalli, A Valli, G Missale, M Pilli, P Fowler, T Giuberti, F V Chisari.   

Abstract

Several lines of experimental evidence suggest that inclusion of core sequences in the hepatitis B vaccine may represent a feasible strategy to increase the efficacy of the vaccination. In order to identify immunodominant core epitopes, peripheral blood T cells purified from 23 patients with acute hepatitis B and different HLA haplotypes were tested with a panel of 18 short synthetic peptides (15 to 20 amino acids [AA]) covering the entire core region. All patients except one showed a strong T cell proliferative response to a single immunodominant 20 amino acid sequence located within the aminoterminal half of the core molecule. Two additional important sequences were also identified at the aminoterminal end and within the carboxyterminal half of the core molecule. These sequences were able to induce significant levels of T cell proliferation in 69 and 73% of the patients studied, respectively. T cell response to these epitopes was HLA class II restricted. The observations that (a) polyclonal T cell lines produced by PBMC stimulation with native HBcAg were specifically reactive with the relevant peptides and that (b) polyclonal T cell lines produced with synthetic peptides could be restimulated with native HBcAg, provide evidence that AA sequences contained within the synthetic peptides represent real products of the intracellular processing of the native core molecule. In conclusion, the identification of immunodominant T cell epitopes within the core molecule provides the molecular basis for the design of alternative and hopefully more immunogenic vaccines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711541      PMCID: PMC296022          DOI: 10.1172/JCI115280

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection.

Authors:  C Ferrari; A Penna; A Bertoletti; A Valli; A D Antoni; T Giuberti; A Cavalli; M A Petit; F Fiaccadori
Journal:  J Immunol       Date:  1990-11-15       Impact factor: 5.422

2.  Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site.

Authors:  D R Milich; A McLachlan; G B Thornton; J L Hughes
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

3.  Protective immunisation against hepatitis B with an internal antigen of the virus.

Authors:  K Murray; S A Bruce; P Wingfield; P van Eerd; A de Reus; H Schellekens
Journal:  J Med Virol       Date:  1987-10       Impact factor: 2.327

4.  Distinct forms of both alpha and beta subunits are present in the human Ia molecular pool.

Authors:  R S Accolla; N Gross; S Carrel; G Corte
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

5.  Precore sequence of hepatitis B virus inducing e antigen and membrane association of the viral core protein.

Authors:  A Uy; V Bruss; W H Gerlich; H G Köchel; R Thomssen
Journal:  Virology       Date:  1986-11       Impact factor: 3.616

6.  A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees.

Authors:  Y Itoh; E Takai; H Ohnuma; K Kitajima; F Tsuda; A Machida; S Mishiro; T Nakamura; Y Miyakawa; M Mayumi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen.

Authors:  D R Milich; A McLachlan
Journal:  Science       Date:  1986-12-12       Impact factor: 47.728

8.  Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B.

Authors:  C Ferrari; A Penna; T Giuberti; M J Tong; E Ribera; F Fiaccadori; F V Chisari
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

9.  Protection against hepatitis B virus infection by immunization with hepatitis B core antigen.

Authors:  S Iwarson; E Tabor; H C Thomas; P Snoy; R J Gerety
Journal:  Gastroenterology       Date:  1985-03       Impact factor: 22.682

10.  Functional characterization of cloned intrahepatic, hepatitis B virus nucleoprotein-specific helper T cell lines.

Authors:  C Ferrari; M U Mondelli; A Penna; F Fiaccadori; F V Chisari
Journal:  J Immunol       Date:  1987-07-15       Impact factor: 5.422

View more
  65 in total

Review 1.  Immunopathogenesis of viral hepatitis.

Authors:  M U Mondelli
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  The underlying mechanisms for the "isolated positivity for the hepatitis B surface antigen (HBsAg)" serological profile.

Authors:  Robério Amorim de Almeida Pondé
Journal:  Med Microbiol Immunol       Date:  2010-05-11       Impact factor: 3.402

Review 3.  Review of cytokine profiles in patients with hepatitis.

Authors:  Qiao-Ling Sun; Wei Ran
Journal:  World J Gastroenterol       Date:  2004-06-15       Impact factor: 5.742

4.  Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.

Authors:  G Missale; R Bertoni; V Lamonaca; A Valli; M Massari; C Mori; M G Rumi; M Houghton; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Association between frequency of amino acid changes in core region of hepatitis B virus (HBV) and the presence of precore mutation in Japanese HBV carriers.

Authors:  T Karasawa; T Shirasawa; Y Okawa; A Kuramoto; N Shimada; Y Aizawa; M Zeniya; G Toda
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

6.  Comparative antigenicity and immunogenicity of hepadnavirus core proteins.

Authors:  Jean-Noel Billaud; Darrell Peterson; Florian Schödel; Antony Chen; Matti Sallberg; Fermin Garduno; Phillip Goldstein; Wendy McDowell; Janice Hughes; Joyce Jones; David Milich
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

7.  A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B.

Authors:  H M Diepolder; M C Jung; E Keller; W Schraut; J T Gerlach; N Grüner; R Zachoval; R M Hoffmann; C A Schirren; S Scholz; G R Pape
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

8.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

Authors:  C Boni; A Bertoletti; A Penna; A Cavalli; M Pilli; S Urbani; P Scognamiglio; R Boehme; R Panebianco; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

9.  Full-length hepatitis B virus sequences from naïve patients with fluctuation of viral load during ADV monotherapy.

Authors:  Yongwei Li; Mingfen Zhu; Yunwei Guo; Wei Chen; Gang Li
Journal:  Virus Genes       Date:  2009-12-12       Impact factor: 2.332

10.  T-Cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge.

Authors:  S Menne; J Maschke; M Lu; H Grosse-Wilde; M Roggendorf
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.